La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zydus Lifesciences Crescita futura

Future criteri di controllo 0/6

Zydus Lifesciences prevede che gli utili e i ricavi cresceranno rispettivamente di 3% e 6.9% all'anno. Si prevede che l'EPS crescerà di 2.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 17.1% in 3 anni.

Informazioni chiave

3.2%

Tasso di crescita degli utili

2.9%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.6%
Tasso di crescita dei ricavi	6.9%
Rendimento futuro del capitale proprio	17.1%
Copertura analitica	Good
Ultimo aggiornamento	21 Aug 2024

Aggiornamenti recenti sulla crescita futura

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Recent updates

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

Previsioni di crescita degli utili e dei ricavi

NSEI:ZYDUSLIFE - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	248,554	44,014	42,558	N/A	18
3/31/2026	240,774	48,109	42,599	N/A	29
3/31/2025	224,494	45,634	35,058	N/A	31
6/30/2024	206,153	41,685	N/A	N/A	N/A
3/31/2024	195,474	38,365	23,213	32,279	N/A
12/31/2023	190,241	29,562	N/A	N/A	N/A
9/30/2023	187,760	28,109	28,078	37,726	N/A
6/30/2023	184,127	25,262	N/A	N/A	N/A
3/31/2023	172,374	19,649	16,579	26,888	N/A
12/31/2022	164,335	20,785	N/A	N/A	N/A
9/30/2022	157,110	19,629	8,934	20,209	N/A
6/30/2022	153,361	21,710	N/A	N/A	N/A
3/31/2022	151,099	22,416	10,146	21,045	N/A
12/31/2021	157,609	23,267	N/A	N/A	N/A
9/30/2021	157,389	23,269	17,283	28,059	N/A
6/30/2021	156,130	22,600	N/A	N/A	N/A
3/31/2021	144,035	22,016	24,399	32,939	N/A
12/31/2020	150,076	18,465	N/A	N/A	N/A
9/30/2020	148,501	16,932	18,757	27,798	N/A
6/30/2020	143,967	13,270	N/A	N/A	N/A
3/31/2020	142,531	11,766	20,274	29,315	N/A
12/31/2019	142,338	12,448	N/A	N/A	N/A
9/30/2019	141,736	13,816	26,553	34,629	N/A
6/30/2019	137,682	16,919	N/A	N/A	N/A
3/31/2019	131,656	18,488	2,245	12,819	N/A
12/31/2018	126,706	19,954	N/A	N/A	N/A
9/30/2018	123,526	20,305	N/A	N/A	N/A
6/30/2018	126,133	21,168	N/A	N/A	N/A
3/31/2018	119,049	17,946	N/A	9,193	N/A
12/31/2017	111,691	15,705	N/A	N/A	N/A
9/30/2017	102,206	13,511	N/A	N/A	N/A
6/30/2017	93,397	12,277	N/A	N/A	N/A
3/31/2017	93,765	14,904	N/A	13,117	N/A
12/31/2016	97,494	11,323	N/A	N/A	N/A
9/30/2016	97,971	12,812	N/A	N/A	N/A
6/30/2016	97,221	14,186	N/A	N/A	N/A
3/31/2016	94,268	19,339	N/A	18,935	N/A
12/31/2015	95,901	14,843	N/A	N/A	N/A
9/30/2015	92,453	13,766	N/A	N/A	N/A
6/30/2015	89,795	12,638	N/A	N/A	N/A
3/31/2015	86,513	11,506	N/A	9,936	N/A
12/31/2014	82,955	10,394	N/A	N/A	N/A
9/30/2014	79,777	9,435	N/A	N/A	N/A
6/30/2014	76,165	8,488	N/A	N/A	N/A
3/31/2014	72,034	8,036	N/A	9,028	N/A
12/31/2013	68,204	8,266	N/A	N/A	N/A
9/30/2013	65,528	7,430	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di ZYDUSLIFE ( 3% all'anno) è inferiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Si prevede che gli utili di ZYDUSLIFE ( 3% all'anno) cresceranno più lentamente rispetto al mercato Indian ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ZYDUSLIFE cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di ZYDUSLIFE ( 6.9% all'anno) crescerà più lentamente rispetto al mercato Indian ( 10% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ZYDUSLIFE ( 6.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di ZYDUSLIFE sarà basso tra 3 anni ( 17.1 %).

Zydus Lifesciences Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Consensus EPS estimates increase by 10%

Price target increased by 9.2% to ₹925

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Recent updates

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Price target increased by 7.6% to ₹536

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Zydus Group Reportedly Looks to Sell Cliantha Research

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Sirolimus Tablets, 1 Mg and 2 Mg